SCHEMBL19922906

SCHEMBL19922906

CCOC(=O)CNC(=O)c1ccc(C(O)CCc2ccc(Cl)cc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
MAPT P10636 2/20 0.50
RAB9A P51151 5/20 0.49
NPC1 O15118 4/20 0.49
EPHX2 P34913 2/20 0.48
SMN1; SMN2 Q16637 7/20 0.48
POLB P06746 3/20 0.45
GAA P10253 2/20 0.45
ALDH1A1 P00352 2/20 0.45
KDM4E B2RXH2 1/20 0.45
CTDSP1 Q9GZU7 1/20 0.45
F2 P00734 1/20 0.44
F10 P00742 1/20 0.44
TP53 P04637 2/20 0.43
HPGD P15428 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C19 P33261 1/20 0.43
GFER P55789 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19922886 0.89 SMN1; SMN2 (0.47) MEN1KMT2AMAPTRAB9ANPC1
SCHEMBL19922925 0.88 MEN1 (0.51) MEN1KMT2AMAPTRAB9ANPC1
SCHEMBL22282956 0.84 MAPT (0.52) MEN1KMT2AMAPTEPHX2SMN1; SMN2
SCHEMBL10898232 0.83 MEN1 (0.72) MEN1KMT2AMAPTRAB9ANPC1
Ethyl Propionate SCHEMBL28309072 0.81 F2 (0.50) MEN1KMT2AMAPTEPHX2SMN1; SMN2
SCHEMBL7625129 0.79 MEN1 (0.54) MEN1KMT2AMAPTRAB9ANPC1
SCHEMBL26814829 0.78 RAB9A (0.63) MEN1KMT2AMAPTRAB9ANPC1
SCHEMBL19923005 0.78 SMN1; SMN2 (0.46) MEN1KMT2AMAPTRAB9ANPC1
SCHEMBL10076252 0.75 RAB9A (0.67) MEN1KMT2AMAPTRAB9ANPC1
SCHEMBL11365241 0.74 MAPT (0.63) MEN1KMT2AMAPTRAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3510022-B1 INDOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2020-08-05 EP disclosed
EP-3510022-A1 INDOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS Janssen Pharmaceutica NV (BE) 2019-07-17 EP disclosed
US-10251864-B2 Indole derivatives useful as glucagon receptor antagonists JANSSEN PHARMACEUTICA NV (BE) 2019-04-09 US disclosed
US-10251864-B2 Indole derivatives useful as glucagon receptor antagonists JANSSEN PHARMACEUTICA NV (BE) 2019-04-09 US disclosed
WO-2018048761-A1 INDOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2018-03-15 WO disclosed
US-20180064686-A1 INDOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2018-03-08 US disclosed
US-20180064686-A1 INDOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2018-03-08 US disclosed
US-20180064686-A1 INDOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2018-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10251864-B2 Indole derivatives useful as glucagon receptor antagonists GPR119, GIPR, GLP1R MEN1 3474/4885KMT2A 2396/4885MAPT 4089/4885
US-20180064686-A1 INDOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS GPR119, GIPR, GLP1R MEN1 3474/4885KMT2A 2396/4885MAPT 4089/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.